120,995 Shares in Progyny, Inc. $PGNY Purchased by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP bought 120,995 Progyny shares worth approximately $3.49 million, while institutional investors collectively own 94.93% of the company.
• Progyny reported quarterly EPS of $0.55, beating estimates of $0.33, as revenue rose 5.3% year over year to $350.51 million. The company also authorized a $200 million share-repurchase program covering up to 10.3% of outstanding shares.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $34.36, compared with the stock’s reported price of $27.13.

Corient Private Wealth LP purchased a new position in Progyny, Inc. (NASDAQ:PGNY - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 120,995 shares of the company's stock, valued at approximately $3,488,000. Corient Private Wealth LP owned approximately 0.16% of Progyny as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PGNY. Amundi lifted its position in Progyny by 82.6% during the second quarter. Amundi now owns 19,395 shares of the company's stock valued at $559,000 after purchasing an additional 8,772 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Progyny in the 2nd quarter worth approximately $1,188,000. Nykredit A S bought a new stake in Progyny in the 2nd quarter worth approximately $38,000. Headlands Technologies LLC bought a new stake in Progyny in the 2nd quarter worth approximately $499,000. Finally, Two Sigma Securities LLC purchased a new stake in Progyny during the 2nd quarter valued at $551,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Price Performance

Shares of PGNY stock opened at $27.13 on Monday. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of 29.49, a PEG ratio of 1.87 and a beta of 0.99. Progyny, Inc. has a one year low of $16.10 and a one year high of $33.06. The company's fifty day moving average price is $28.37 and its 200-day moving average price is $24.30.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company had revenue of $350.51 million for the quarter, compared to the consensus estimate of $349.05 million. During the same quarter last year, the company earned $0.19 EPS. The firm's quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Equities research analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Progyny declared that its Board of Directors has approved a share buyback plan on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.

Insider Activity at Progyny

In other news, Director Kevin Gordon sold 11,500 shares of the firm's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the transaction, the director owned 6,792 shares in the company, valued at $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 9.90% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have issued reports on PGNY. BTIG Research raised their target price on Progyny from $30.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, July 24th. Bank of America upped their price target on shares of Progyny from $29.00 to $31.00 and gave the company a "buy" rating in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. increased their price objective on shares of Progyny from $27.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, August 21st. Leerink Partners set a $38.00 price objective on shares of Progyny in a research note on Wednesday, July 22nd. Finally, Jefferies Financial Group set a $33.00 price objective on shares of Progyny in a report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $34.36.

Progyny Company Profile

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company's services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.